FDA Approves Another Over-the-Counter Naloxone Nasal Spray

THURSDAY, June 18, 2026 (HealthDay News) -- The U.S. Food and Drug Administration has approved another over-the-counter intranasal naloxone product, Rextovy (naloxone hydrochloride), for the emergency treatment of opioid overdose.The 4-mg nasal spray is available for purchase by consumers without a prescription in pharmacies, convenience stores, and online. The product's packaging includes five-step pictorial directions, including calling 911 after giving the first dose.When regaining consciousness after the overdose reversal, some people may experience symptoms such as shaking, sweating, nausea, or feeling angry. The product is safe to use even if it is uncertain whether opioids are the cause of the overdose."Reducing opioid overdose deaths is a top priority for FDA," Mike Davis M.D., Ph.D., from the FDA Center for Drug Evaluation and Research, said in a statement. "Today's approval of an additional over-the-counter naloxone nasal spray helps broaden access and offers an additional option for consumers. Empowering people without medical training to take immediate action with these products has been proven to save lives."Nonprescription approval of Rextovy was granted to Amphastar Pharmaceuticals.More Information.Sign up for our weekly HealthDay newsletter

FDA Approves Another Over-the-Counter Naloxone Nasal Spray

Related Stories

CDC, FDA Tackle New World Screwworm, Including Drug Authorization

Organic Baby Formula Recalled Following Botulism Cases

FDA Approves Rapid-Acting Inhaled Insulin for Children

FDA Approves Xocova for COVID-19 Postexposure Prophylaxis